Free Trial
NASDAQ:WGS

GeneDx (WGS) Stock Price, News & Analysis

GeneDx logo
$91.61 +1.82 (+2.03%)
Closing price 01:00 PM Eastern
Extended Trading
$90.65 -0.96 (-1.05%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About GeneDx Stock (NASDAQ:WGS)

Key Stats

Today's Range
$88.79
$92.79
50-Day Range
$56.44
$116.97
52-Week Range
$25.32
$117.75
Volume
328,245 shs
Average Volume
816,175 shs
Market Capitalization
$2.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.13
Consensus Rating
Moderate Buy

Company Overview

GeneDx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

WGS MarketRank™: 

GeneDx scored higher than 44% of companies evaluated by MarketBeat, and ranked 745th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GeneDx has only been the subject of 4 research reports in the past 90 days.

  • Read more about GeneDx's stock forecast and price target.
  • Earnings Growth

    Earnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GeneDx is -64.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GeneDx is -64.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GeneDx has a P/B Ratio of 10.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about GeneDx's valuation and earnings.
  • Percentage of Shares Shorted

    15.03% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GeneDx has recently increased by 3.02%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    GeneDx does not currently pay a dividend.

  • Dividend Growth

    GeneDx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.03% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GeneDx has recently increased by 3.02%, indicating that investor sentiment is decreasing.
  • News Sentiment

    GeneDx has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for GeneDx this week, compared to 9 articles on an average week.
  • Search Interest

    Only 4 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GeneDx insiders have sold 23.56% more of their company's stock than they have bought. Specifically, they have bought $5,601,000.00 in company stock and sold $6,920,533.00 in company stock.

  • Percentage Held by Insiders

    29.60% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GeneDx's insider trading history.
Receive WGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter.

WGS Stock News Headlines

Image of dna strand and data processing over world map on black background. Global technology, computing and digital interface concept digitally generated image. — Photo
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (WGS)
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
GeneDx (NASDAQ:WGS) Price Target Raised to $115.00 at Guggenheim
See More Headlines

WGS Stock Analysis - Frequently Asked Questions

GeneDx's stock was trading at $76.86 at the start of the year. Since then, WGS shares have increased by 19.2% and is now trading at $91.61.

GeneDx Holdings Corp. (NASDAQ:WGS) announced its quarterly earnings results on Wednesday, April, 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.11 by $0.17. The company earned $87.12 million during the quarter, compared to analyst estimates of $79.90 million. GeneDx had a positive trailing twelve-month return on equity of 10.17% and a negative net margin of 11.69%.
Read the conference call transcript
.

GeneDx shares reverse split before market open on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
4/30/2025
Today
7/03/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:WGS
Fax
N/A
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$90.13
High Stock Price Target
$118.00
Low Stock Price Target
$45.00
Potential Upside/Downside
-2.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
95.43
P/E Growth
N/A
Net Income
-$52.29 million
Pretax Margin
-11.63%

Debt

Sales & Book Value

Annual Sales
$305.45 million
Cash Flow
$1.05 per share
Price / Cash Flow
88.24
Book Value
$8.75 per share
Price / Book
10.58

Miscellaneous

Free Float
20,087,000
Market Cap
$2.64 billion
Optionable
Optionable
Beta
2.01
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:WGS) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners